|
CRVS Corvus Pharmaceuticals Inc 1626971 |
| Income Statement |
|
Net Income
|
2026-06-30
|
$-17,959,000.00 |
| Balance Sheet |
|
Current Assets
|
$220,965,000.00 |
|
Assets
|
$239,274,000.00 |
|
Current Liabilities
|
$13,672,000.00 |
|
Liabilities
|
$13,946,000.00 |
|
Equity
|
$225,328,000.00 |
|
Shares Out
|
84120944.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-25,772,000.00 |
|
Investing Cash Flow
|
$-150,811,000.00 |
| Market Analysis |
Market Cap
|
$1,205,453,127.52 |
|
Price
|
$14.33 |
|
BVPS
|
2.68 |
|
PB
|
5.35 |
|
EPS
|
-0.19 |
|
FCF
|
$-26,445,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:35 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:25 |
|
| Apr |
May |
Jun |
| 2026-03-12 |
-0.15 |
|
|
2026-05-07 |
-0.15 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-07 |
-0.10 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-04 |
-0.12 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view CRVS documents filed with the SEC.
CRVS Filings
Clear
